Q1 2018 Rigel Pharmaceuticals Inc Earnings Call
Conference Call Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals Inc Conference call will be held on May 1, 2018. During the earnings conference call's session Rigel Pharmaceuticals Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Rigel Pharmaceuticals Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
Rigel Pharmaceuticals, Inc. was incorporated in Delaware in June 1996, and is based in South San Francisco, California. We are a clinicalstage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Our pioneering research focuses on signaling pathways that are critical to disease mechanisms. Our current clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for immune thrombocytopenic purpura (ITP); a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN). In addition, we have two oncology product candidates in Phase 1 development with partners BerGenBio AS (BergenBio) and Daiichi Sankyo (Daiichi).Read more Conference Call